TITLE

Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes

AUTHOR(S)
Redmon, J. Bruce; Reck, Kristell P.; Raatz, Susan K.; Swanson, Joyce E.; Kwong, Christine A.; Ji, Hong; Thomas, William; Bantle, John P.
PUB. DATE
June 2005
SOURCE
Diabetes Care;Jun2005, Vol. 28 Issue 6, p1311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE -- To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS -- A total of 59 overweight or obese individuals with type 2 diabetes were randomly assigned to either a combination therapy weight loss program for 2 years (C therapy) or a standard therapy weight loss program for 1 year followed by a combination therapy weight loss program in the 2nd year (S/C therapy). C therapy combined the use of meal replacement products, repetitive intermittent low-calorie-diet weeks, and pharmacologic therapy with sibutramine. Outcome measures included changes in weight, glycemic control, plasma lipids, blood pressure, and body composition over 2 years. RESULTS -- A total of 48 participants (23 in the C therapy group and 25 in the S/C therapy group) completed 2 years of study. After 2 years, the C therapy' group had weight loss of 4.6 ± 1.2 kg (P < 0.001) and a decrease in HbA1c of 0.5 ± 0.3% (P = 0.08) from baseline. At 2 years, the C therapy group had significant reductions in BMI, fat mass, lean body mass, and systolic blood pressure. The S/C therapy group showed changes in weight and HbA1c in year 2 of the study that were similar to those demonstrated by the C therapy group in year 1. CONCLUSIONS -- This combination weight loss program resulted in significant weight loss and improved diabetes control over a 2-year period in overweight subjects with type 2 diabetes.
ACCESSION #
17326003

 

Related Articles

  • Evaluation of Glycemic Parameters in Obese Diabetic Patients Treated with Phentermine and Topiramate: Outcomes in a Private Practice Setting. Najarian, Thomas; Rowsemitt, Carol N.; Charbonneau, Vicki U.; Peterson, Craig A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA560 

    Effective and well-tolerated treatments are needed for obese patients with type 2 diabetes. Low-dose combinations of phentermine and topiramate (P/T) have demonstrated significant weight loss in a controlled trial using a proprietary formulation, and have been used for the treatment of obesity...

  • The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient. Kozakowski, Jarosław; Lebovitz, Harold E.; Kiciak, Adam; Zgliczyński, Wojciech; Tarnowski, Wiesław // Videosurgery & Other Miniinvasive Techniques / Wideochirurgia i;Dec2014, Vol. 9 Issue 4, p627 

    Obesity and type 2 diabetes mellitus have reached epidemic proportions worldwide. As the majority of antidiabetic medications are of limited efficacy and patient adherence to long-term therapy is one of the main limiting factors of effective blood glucose and body weight control, new therapies...

  • Low-Carb Improvements. Karl, E. // Diabetes Health;Sep2005, Vol. 14 Issue 9, p32 

    Discusses research being done on the benefits of a low-carbohydrate diet to obese people with type 2 diabetes. Reference to a study published in the March 2005 issue of "Annals of Internal Medicine" journal; Details of the diet assigned to the patients involved in the study; Recorded weight...

  • Rimonabant: An Answer to Overweight in Diabetes? Kuritzky, Louis // Travel Medicine Advisor;Feb2007, Vol. 17 Issue 2, Special section p3 

    The article discusses research being done on the impact of Rimonabant (RBT) on overweight diabetic subjects with reference to a study conducted by A. J. Scheen et al, published in a 2006 issue of "Lancet." According to the article, the use of RBT resulted to weight loss in non-diabetic...

  • Call for more gastric banding for type 2 diabetes.  // British Journal of Hospital Medicine (17508460);Jul2009, Vol. 70 Issue 7, p377 

    The article reports on the call for greater consideration of gastric banding as an option for obese people with type 2 diabetes in Great Britain. It mentions that the gastric banding procedure is a highly effective option for selected obese patients who fail to reduce their weight through...

  • Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery. Zalesin, Kerstyn C.; Krause, Kevin R.; Chengelis, David L.; McCullough, Peter A. // Vascular Disease Prevention;May2008, Vol. 5 Issue 2, p75 

    Background: The association between body mass index (BMI) and the development of type 2 diabetes (T2DM) is well established. The determinants of the resolution of T2DM with weight reduction after bariatric surgery, however, are not fully understood. Objective: Examine the course of T2DM during...

  • Key Global Literature. Fonseca, Vivian // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2339 

    Provides information on a randomized study of orlistat in combination with a weight management program in obese patients with type 2 diabetes treated with metformin. Comparison between orlistat treatment and placebo; Impact of orlistaton glycemic control and the lipid profile in type 2 diabetes.

  • Amphetamine-Like Analogues in Diabetes: Speeding towards Ketogenesis. Branis, Natalia M.; Wittlin, Steven D. // Case Reports in Endocrinology;4/19/2015, Vol. 2015, p1 

    Obesity is common in patients with type 1 and type 2 diabetes. Amphetamine-like analogues comprise the most popular class of weight loss medications. We present a case of a 34-year-old African American female with a history of type 1 diabetes, dyslipidemia, and obesity who developed diabetic...

  • Progressive Reduction in Body Weight with Pramlintide Therapy in Obese Subjects with Type 2 Diabetes Treated with Diet and Exercise and/or Metformin. Edelman, Steve; Lush, Cameron; Kesty, Nicole; Burns, Colleen; Weyer, Christian; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, has several clinical effects relevant to obesity, including meal-related satiation, reduced food intake, and weight loss. We previously reported that 16-wk PRAM treatment resulted in a placebo (PBO)-corrected change in body weight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics